Literature DB >> 6199510

Mechanism of RNA primer removal by the RNase H activity of avian myeloblastosis virus reverse transcriptase.

J J Champoux, E Gilboa, D Baltimore.   

Abstract

The single-stranded DNA containing the Moloney murine leukemia virus origin for plus-strand synthesis was cloned in M13mp2 and used as a template for avian myeloblastosis virus reverse transcriptase in the presence of Moloney RNA which had been treated with pancreatic RNase A. The RNA pieces containing the polypurine stretch near the plus-strand origin were processed, presumably by RNase H, to generate primers for DNA synthesis which initiated both at the correct origin site and at one nucleotide downstream from the correct site. Approximately 50% of the labeled DNA fragments synthesized under these conditions retained the priming RNA on their 5' ends. When the isolated fragments were hybridized back to the template DNA and again treated with the reverse transcriptase, all of the RNA was removed from the labeled DNA. By using 5'-end-labeled pancreatic RNase A-resistant fragments, it was possible to show that the RNA primers were removed intact. It appears from these results that the RNase H activity associated with the enzyme shows a preference for cutting at the junction between the RNA and DNA moieties of such complexes and therefore is ideally suited for removing RNA primers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199510      PMCID: PMC255525     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Association of an endoribonuclease with the avian myeloblastosis virus deoxyribonucleic acid polymerase.

Authors:  D Baltimore; D F Smoler
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

2.  Association of viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids.

Authors:  K Mölling; D P Bolognesi; H Bauer; W Büsen; H W Plassmann; P Hausen
Journal:  Nat New Biol       Date:  1971-12-22

3.  In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of Moloney murine leukemia virus.

Authors:  E Gilboa; S Goff; A Shields; F Yoshimura; S Mitra; D Baltimore
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

4.  Reverse transcriptase from avian myeloblastosis virus.

Authors:  G E Houts; M Miyagi; C Ellis; D Beard; J W Beard
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

5.  Mechanism of release of the avian rotavirus tRNATrp primer molecule from viral DNA by ribonuclease H during reverse transcription.

Authors:  C A Omer; A J Faras
Journal:  Cell       Date:  1982-10       Impact factor: 41.582

Review 6.  The reverse transcriptase.

Authors:  I M Verma
Journal:  Biochim Biophys Acta       Date:  1977-03-21

7.  Extensive in vitro transcription of rous sarcoma virus RNA by avian myeloblastosis virus DNA polymerase and concurrent activation of the associated RNase H.

Authors:  J L Darlix; P A Bromley; P F Spahr
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

8.  RNase H hydrolysis of the 5' terminus of the avian sarcoma virus genome during reverse transcription.

Authors:  M S Collett; P Dierks; J T Parsons; A J Faras
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

9.  Ribonuclease H: a ubiquitous activity in virions of ribonucleic acid tumor viruses.

Authors:  D P Grandgenett; G F Gerard; M Green
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

10.  Measurement of the sequence complexity of cloned Moloney murine leukemia virus 60 to 70S RNA: evidence for a haploid genome.

Authors:  H Fan; M Paskind
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

View more
  32 in total

1.  Specificities involved in the initiation of retroviral plus-strand DNA.

Authors:  G X Luo; L Sharmeen; J Taylor
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  The self primer of the long terminal repeat retrotransposon Tf1 is not removed during reverse transcription.

Authors:  Angela Atwood-Moore; Kenneth Yan; Robert L Judson; Henry L Levin
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Abortive reverse transcription by mutants of Moloney murine leukemia virus deficient in the reverse transcriptase-associated RNase H function.

Authors:  N Tanese; A Telesnitsky; S P Goff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis.

Authors:  J M Lien; C E Aldrich; W S Mason
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

5.  Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by human immunodeficiency and avian myeloblastosis virus reverse transcriptases.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1994-09-11       Impact factor: 16.971

6.  Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

7.  Expression of an Mg2+-dependent HIV-1 RNase H construct for drug screening.

Authors:  Richard V Farias; Deborah A Vargas; Andres E Castillo; Beatriz Valenzuela; Marie L Coté; Monica J Roth; Oscar Leon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  Posttranscriptional modification of retroviral primers is required for late stages of DNA replication.

Authors:  B P Burnett; C S McHenry
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

9.  RNase H-mediated release of the retrovirus RNA polyadenylate tail during reverse transcription.

Authors:  J C Olsen; K F Watson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

10.  The role of Moloney murine leukemia virus RNase H activity in the formation of plus-strand primers.

Authors:  A J Rattray; J J Champoux
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.